|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
|
|
|
|||||||||
|
|||||||||||
|
J Am Coll Cardiol, 1999; 33:1863-1869 © 1999 by the American College of Cardiology Foundation |
* Divisione di Cardiochirurgia, Università di Roma Tor Vergata, European Hospital, Rome, Italy
Istituto di Cardiologia, Università Cattolica del Sacro Cuore, Rome, Italy
Cattedra di Clinica Medica I, Università La Sapienza, Rome, Italy
Manuscript received October 15, 1998; revised manuscript received January 25, 1999, accepted February 15, 1999.
Reprint requests and correspondence: Dr. Fabrizio Tomai, Divisione di Cardiochirurgia, Università di Roma Tor Vergata, European Hospital, via Portuense 700, 00149 Rome, Italy
OBJECTIVES
We attempted to establish whether naloxone, an opioid receptor antagonist, abolishes the adaptation to ischemia observed in humans during coronary angioplasty after repeated balloon inflations.
BACKGROUND
Experimental studies indicate that myocardial opioid receptors are involved in ischemic preconditioning.
METHODS
Twenty patients undergoing angioplasty for an isolated stenosis of a major epicardial coronary artery were randomized to receive intravenous infusion of naloxone or placebo during the procedure. Intracoronary electrocardiogram and cardiac pain (using a 100-mm visual analog scale) were determined at the end of the first two balloon inflations. Average peak velocity in the contralateral coronary artery during balloon occlusion, an index of collateral recruitment, was also assessed by using a Doppler guide wire in the six patients of each group with a stenosis on the left anterior descending coronary artery.
RESULTS
In naloxone-treated patients, ST-segment changes and cardiac pain severity during the second inflation were similar to those observed during the first inflation (12 ± 6 vs. 11 ± 7 mm, p = 0.3, and 58 ± 13 vs. 56 ± 12 mm, p = 0.3, respectively), whereas in placebo-treated patients, they were significantly less (6 ± 3 vs. 13 ± 6 mm, p = 0.002 and 31 ± 21 vs. 55 ± 22 mm, p = 0.008, respectively). In both naloxone- and placebo-treated patients, average peak velocity significantly increased from baseline to the end of the first inflation (p = 0.04 and p = 0.02, respectively), but it did not show any further increase during the second inflation.
CONCLUSIONS
The adaptation to ischemia observed in humans after two sequential coronary balloon inflations is abolished by naloxone and is independent of collateral recruitment. Thus, it is due to ischemic preconditioning and is, at least partially, mediated by opioid receptors, suggesting their presence in the human heart.
| ||||||||
This article has been cited by other articles:
|
|
 |
|
  G. Niccoli, L. Altamura, A. Fabretti, G. A. Lanza, L. M. Biasucci, A. G. Rebuzzi, A. M. Leone, I. Porto, F. Burzotta, C. Trani, et al. Ethanol Abolishes Ischemic Preconditioning in Humans J. Am. Coll. Cardiol., January 22, 2008; 51(3): 271 - 275. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Mentzer Jr, M. S. Jahania, and R. D. Lasley Myocardial Protection Card. Surg. Adult, January 1, 2008; 3(2008): 443 - 464. [Full Text]
|
|
|
|
 |
|
 E. W. Dickson, C. P. Hogrefe, P. S. Ludwig, L. W. Ackermann, L. L. Stoll, and G. M. Denning Exercise enhances myocardial ischemic tolerance via an opioid receptor-dependent mechanism Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H402 - H408. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. R. Gross and G. J. Gross Ligand triggers of classical preconditioning and postconditioning Cardiovasc Res, May 1, 2006; 70(2): 212 - 221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Kloner and S. H. Rezkalla Preconditioning, postconditioning and their application to clinical cardiology Cardiovasc Res, May 1, 2006; 70(2): 297 - 307. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Michael. J. Watson, J. D. S. Holt, S. J. O'Neill, K. Wei, W. Pendergast, G. J. Gross, P. J. Gengo, and K.-J. Chang ARD-353 [4-((2R,5S)-4-(R)-(4-Diethylcarbamoylphenyl)(3-hydroxyphenyl)methyl)-2,5-dimethylpiperazin-1-ylmethyl)benzoic Acid], A Novel Nonpeptide {delta} Receptor Agonist, Reduces Myocardial Infarct Size without Central Effects J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 423 - 430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Argaud, G. Rioufol, M. Lievre, L. Bontemps, P. Legalery, M. Stumpf, G. Finet, R. Itti, X. Andre-Fouet, and M. Ovize Preconditioning during coronary angioplasty: no influence of collateral perfusion or the size of the area at risk Eur. Heart J., November 2, 2004; 25(22): 2019 - 2025. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.W. Broadhead, R.K. Kharbanda, M.J. Peters, and R.J. MacAllister KATP Channel Activation Induces Ischemic Preconditioning of the Endothelium in Humans In Vivo Circulation, October 12, 2004; 110(15): 2077 - 2082. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Pepe, O. W.V van den Brink, E. G Lakatta, and R.-P. Xiao Cross-talk of opioid peptide receptor and {beta}-adrenergic receptor signalling in the heart Cardiovasc Res, August 15, 2004; 63(3): 414 - 422. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T B Lindhardt, N Gadsboll, H Kelbaek, K Saunamaki, J K Madsen, P Clemmensen, B Hesse, and S Haunso Pharmacological modulation of the ATP sensitive potassium channels during repeated coronary occlusions: no effect on myocardial ischaemia or function Heart, April 1, 2004; 90(4): 425 - 430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zaugg, E. Lucchinetti, C. Garcia, T. Pasch, D. R. Spahn, and M. C. Schaub Anaesthetics and cardiac preconditioning. Part II. Clinical implications Br. J. Anaesth., October 1, 2003; 91(4): 566 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. YELLON and J. M. DOWNEY Preconditioning the Myocardium: From Cellular Physiology to Clinical Cardiology Physiol Rev, October 1, 2003; 83(4): 1113 - 1151. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Cao, L. Liu, and D. M. Van Winkle Activation of {delta}- and {kappa}-opioid receptors by opioid peptides protects cardiomyocytes via KATP channels Am J Physiol Heart Circ Physiol, August 7, 2003; 285(3): H1032 - H1039. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Leesar, M. F. Stoddard, Y.-T. Xuan, X.-L. Tang, and R. Bolli Nonelectrocardiographic evidence that both ischemic preconditioning and adenosine preconditioning exist in humans J. Am. Coll. Cardiol., August 6, 2003; 42(3): 437 - 445. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Mentzer Jr., M. S. Jahania, and R. D. Lasley Myocardial Protection Card. Surg. Adult, January 1, 2003; 2(2003): 413 - 438. [Full Text]
|
|
|
|
 |
|
 R. Kato and P. Foex Myocardial protection by anesthetic agents against ischemia-reperfusion injury: an update for anesthesiologists: [La protection myocardique contre les lesions d'ischemie-reperfusion par des anesthesiques : une mise a jour pour les anesthesiologistes] Can J Anesth, October 1, 2002; 49(8): 777 - 791. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M Fryer, J. A Auchampach, and G. J Gross Therapeutic receptor targets of ischemic preconditioning Cardiovasc Res, August 15, 2002; 55(3): 520 - 525. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A Kloner, M. T Speakman, and K. Przyklenk Ischemic preconditioning: a plea for rationally targeted clinical trials Cardiovasc Res, August 15, 2002; 55(3): 526 - 533. [Full Text] [PDF]
|
|
|
|
|
|
D. C. Sigg, J. A. Coles Jr., P. R. Oeltgen, and P. A. Iaizzo Role of delta -opioid receptor agonists on infarct size reduction in swine Am J Physiol Heart Circ Physiol, June 1, 2002; 282(6): H1953 - H1960. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A D Kelion, T P Webb, M A Gardner, O J M Ormerod, G L Shepherd, and A P Banning Does a selective adenosine A1 receptor agonist protect against exercise induced ischaemia in patients with coronary artery disease? Heart, February 1, 2002; 87(2): 115 - 120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. C. Sigg, J. A. Coles Jr, W. J. Gallagher, P. R. Oeltgen, and P. A. Iaizzo Opioid preconditioning: myocardial function and energy metabolism Ann. Thorac. Surg., November 1, 2001; 72(5): 1576 - 1582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Heusch Nitroglycerin and Delayed Preconditioning in Humans : Yet Another New Mechanism for an Old Drug? Circulation, June 19, 2001; 103(24): 2876 - 2878. [Full Text] [PDF]
|
|
|
|
|
|
R. Schulz, P. Gres, and G. Heusch Role of endogenous opioids in ischemic preconditioning but not in short-term hibernation in pigs Am J Physiol Heart Circ Physiol, May 1, 2001; 280(5): H2175 - H2181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Fryer, Y. Wang, A. K. Hsu, and G. J. Gross Essential activation of PKC-{delta} in opioid-initiated cardioprotection Am J Physiol Heart Circ Physiol, March 1, 2001; 280(3): H1346 - H1353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Bell, M. N. Sack, A. Patel, L. H. Opie, and D. M. Yellon Delta opioid receptor stimulation mimics ischemic preconditioning in human heart muscle J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2296 - 2302. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Yellon and A. Dana The Preconditioning Phenomenon : A Tool for the Scientist or a Clinical Reality? Circ. Res., September 29, 2000; 87(7): 543 - 550. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Takasaki, R. A. Wolff, G. L. Chien, and D. M. van Winkle Met5-enkephalin protects isolated adult rabbit cardiomyocytes via delta -opioid receptors Am J Physiol Heart Circ Physiol, December 1, 1999; 277(6): H2442 - H2450. [Abstract] [Full Text] [PDF]
|
|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
